A New Path to Precision.

Rheos is leading the way with molecularly-targeted medicines for patients with autoimmune & inflammatory diseases.

The Challenge:

Today’s treatments fail to address the heterogeneity of autoimmune and inflammatory diseases that affect an estimated 7% of the U.S. population. For many of these chronic, progressive diseases, the majority of patients do not respond to current treatments and many experience challenging side effects.

Our Solution:

Rheos Medicines is developing novel, small molecule medicines to treat autoimmune and inflammatory diseases by targeting the metabolic hubs of the immune system. We are addressing the pathways essential to metabolic regulation of multiple immune cell subtypes to drive system-wide transitions in immunologic function. Using our proprietary MetPM™platform, the Rheos team integrates vast datasets and multi-omics analyses of human immune cells, enabling a new understanding of immunometabolism to identify therapeutic targets and establish molecular signatures to predict patient response.

Rheos is taking a major step forward as we focus on treating autoimmune and inflammatory diseases with greater precision.

Metabolic
Hubs

Interrogate these coordinated access points for system-wide transitions in immune function

Targeted Therapies

Advance molecularly-targeted medicines to improve outcomes in autoimmune and inflammatory diseases

Patient Subsetting

Identify molecular signatures to predict patient response and select the right therapy for every patient

Breadth of Diseases

Expand therapeutics that target fundamental mechanisms of disease across multiple indications

Our
difference is our Team

Come be part of the journey!

Our platform powers our understanding of metabolic hubs, giving us insights into molecular drivers of immune-mediated diseases – so Rheos can develop targeted medicines and direct them to the patients who will respond to treatment.